



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 19487

Title: Targeted Therapies in Gastric Cancer and Future Perspectives

Reviewer's code: 02568380

Reviewer's country: United States

Science editor: Jin-Xin Kong

Date sent for review: 2015-05-12 16:08

Date reviewed: 2015-08-15 03:04

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This is a nice review of current and upcoming targeted therapy in gastric cancer. The Table and Figure are also good. Overall, an excellent review.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 19487

Title: Targeted Therapies in Gastric Cancer and Future Perspectives

Reviewer's code: 00502831

Reviewer's country: Japan

Science editor: Jin-Xin Kong

Date sent for review: 2015-05-12 16:08

Date reviewed: 2015-08-22 13:55

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The authors reported about almost whole recent molecular targeting therapy and clinical trials of new molecular targeting drugs in very detail. But I have some comments and questions. #1. In 3.4. EGFR-Depent Tyrosine Kinase Inhibitors, line 4, the author described Src is involved in EGRC pathways----- . What it's mean? It means EGFR pathway? #2. In 3.4. EGFR-Depent Tyrosine Kinase Inhibitors, is AZD0530 sacaratinib or saracatinib? #3. The authors should add AZD0530, Src, and dacomitinib to Fig. 1. #4. In 5.1. Monoclonal Antibodies Blocking HGF-cMet Pathway, the authors described that in chemotherapy alone group, the Met-high subpopulation had poor prognosis and shorter OS compared to MET-low subpopulation. Why in ECX alone group, the subpopulation of patients with low MET staining rate by IHC had poor prognosis? #5. The authors should add crizotinib to Fig. 1. #6. In 7.5. Insulin Like Growth Factor Inhibitors, there was no explanation about ganitumab.